Chinese ophthalmology infrastructure for GA treatment delivery — the retina specialty departments, intravitreal injection capacity, and ophthalmologist workforce creating the clinical delivery system for GA treatment — represents the market access foundation, with the China Geographic Atrophy Market reflecting clinical infrastructure as a key market development factor.

Chinese retinal specialist capacity — the approximately five thousand to seven thousand Chinese retina specialists capable of performing intravitreal injections and managing GA — representing the clinical workforce that would deliver GA treatments. The existing anti-VEGF injection infrastructure for wet AMD (approximately two million annual intravitreal injections in China) providing the foundation for potential GA complement inhibitor delivery.

Intravitreal injection clinical pathway in China — the ophthalmology departments at Chinese tier-3 hospitals performing intravitreal injections for wet AMD (ranibizumab, aflibercept, conbercept) in injection rooms with standard sterilization protocols — demonstrating the existing infrastructure applicable to GA treatment delivery. The estimated fifteen hundred to two thousand Chinese hospitals with established intravitreal injection programs.

GA treatment frequency and visit burden — the monthly intravitreal injection requirement for GA complement inhibitors creating the clinical visit burden consideration for Chinese patients. The comparison to wet AMD anti-VEGF (also monthly initially, allowing treatment interval extension) creating the patient experience parallel that guides GA treatment adoption expectations.

Do you think the existing wet AMD intravitreal injection infrastructure in China is adequate to support rapid GA treatment uptake once NMPA approval is achieved, or will capacity limitations create access barriers?

FAQ

How developed is intravitreal injection delivery in China? Chinese intravitreal injection capacity: wet AMD treatment: approximately two million annual injections (growing with aging population); anti-VEGF drugs: ranibizumab (Lucentis), aflibercept (Eylea), conbercept (domestic); injection infrastructure: tier-3 hospitals (approximately two thousand): most have dedicated injection room; tier-2 hospitals: growing capability; retinal specialists: approximately five to seven thousand nationwide; geographical distribution: concentrated in tier-1/tier-2 cities; rural access: limited; injection cost: approximately RMB 5,000-15,000 per injection for anti-VEGF (drug + procedure); reimbursement: NHSA (medical insurance) covers wet AMD treatment at national formulary level; overall: established infrastructure from anti-VEGF experience; scalable for GA treatment with adequate supply.

What wet AMD anti-VEGF drugs are approved in China? China wet AMD anti-VEGF market: Lucentis (ranibizumab, Novartis/Roche): NMPA approved, first-line; Eylea (aflibercept, Bayer): NMPA approved, growing adoption; Conbercept (康柏西普, Chengdu Kanghong Pharma): China domestic biosimilar-like anti-VEGF, lower price, significant domestic market share; bevacizumab (off-label use, limited); brolucizumab (Beovu, Novartis): NMPA approved; domestic biosimilar development: multiple anti-VEGF biosimilars in development; commercial significance for GA: established physician experience with intravitreal injections; patient familiarity with injection treatment; injection infrastructure ready; NHSA reimbursement pathway precedent from wet AMD coverage.

#ChinaGeographicAtrophy #IntravitrealsChina #ChineseRetina #WetAMDchina #RetinalSpecialist #OphthalmologyInfrastructure